Executive & Research Teams
Cell Signaling Technology (CST) prides itself on being a company of scientists for scientists. As such, our management has pursued a differentiation strategy based upon providing the highest-quality, best-validated products that are backed by superior technical support. CST provides premium products that are comprehensively validated to function in the experimental procedures required by our customers at universities, government labs, hospitals, biotech and pharmaceutical companies around the globe.
Research at Cell Signaling Technology is focused on antibody platform technologies, proteomics discovery platforms, and mechanistic cancer research. Strong commitments to internal research and technology development efforts are what differentiate us and provide unique scientific insight, novel targets, and superior product development. With an eye on the horizon, CST reinvests a large percentage of its profits into research and development activities.
- Gabriel Cheung Director of Antibody Technologies
- Herbert Haack Head of Clinical Assay
- Peter Hornbeck Director, PhosphoSitePlus®